Precigen Inc. (NASDAQ:PGEN) is one of the 10 Stocks Paying Off Big Time. Precigen rallied for a second day on Monday, surging 11.62 percent to end at $5.38 apiece, as investors loaded portfolios ahead ...

View Precigen Inc PGEN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Precigen (NASDAQ:PGEN) reported a sharp increase in first-quarter 2026 revenue as the company’s first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025. On ...

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. At ...

On Friday, the U.S. Food and Drug Administration (FDA) approved Precigen Inc.’s (NASDAQ:PGEN) Papzimeos (zopapogene imadenovec-drba) for adult patients with recurrent respiratory papillomatosis (RRP).

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in TTEC Holdings Inc (Symbol: TTEC), where a total of 1,093 contracts have traded so far, ...

Patient Capital Management, a value investing firm, released its “Patient Opportunity Equity Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, ...

She held this position from 2015 to 2017. She is currently the President, Chief Executive Officer & Director at Precigen, Inc. since 2020 and the President at PGEN Therapeutics, Inc. since 2017. Dr.